Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Accumulated Expenses (2022 - 2025)

Historic Accumulated Expenses for Taysha Gene Therapies (TSHA) over the last 4 years, with Q3 2025 value amounting to $17.7 million.

  • Taysha Gene Therapies' Accumulated Expenses rose 4045.05% to $17.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.7 million, marking a year-over-year increase of 4045.05%. This contributed to the annual value of $12.9 million for FY2024, which is 470.53% up from last year.
  • Taysha Gene Therapies' Accumulated Expenses amounted to $17.7 million in Q3 2025, which was up 4045.05% from $12.2 million recorded in Q2 2025.
  • In the past 5 years, Taysha Gene Therapies' Accumulated Expenses ranged from a high of $26.6 million in Q1 2022 and a low of $10.8 million during Q1 2025
  • Moreover, its 4-year median value for Accumulated Expenses was $13.6 million (2023), whereas its average is $15.7 million.
  • Per our database at Business Quant, Taysha Gene Therapies' Accumulated Expenses tumbled by 3951.2% in 2024 and then soared by 4045.05% in 2025.
  • Quarter analysis of 4 years shows Taysha Gene Therapies' Accumulated Expenses stood at $18.3 million in 2022, then plummeted by 32.83% to $12.3 million in 2023, then grew by 4.71% to $12.9 million in 2024, then surged by 37.68% to $17.7 million in 2025.
  • Its last three reported values are $17.7 million in Q3 2025, $12.2 million for Q2 2025, and $10.8 million during Q1 2025.